Should Patients with Venous Thromboembolism Be Screened for Thrombophilia?

American Journal of Medicine

Volumn 121, Issue 6, 2008, Pages 458-463

  Dalen, James E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Hypercoagulability; Idiopathic venous thromboembolism; Provoked venous thromboembolism; Recurrent venous thromboembolism; Thrombophilia

Indexed keywords

ANTITHROMBIN III; ANTIVITAMIN K; BLOOD CLOTTING FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CLINICAL DECISION MAKING; FAMILY HISTORY; HUMAN; HYPERHOMOCYSTEINEMIA; ORAL CONTRACEPTION; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK; SCREENING; STATISTICAL SIGNIFICANCE; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FACTOR V; HUMANS; HYPERHOMOCYSTEINEMIA; MASS SCREENING; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VITAMIN K; WARFARIN;

EID: 43749123901     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.10.042     Document Type: Review

References (34)

1. Virchow R. Gesammalte Abhandlungen zur Wissenschaftlichen Medtzin (1856), Medinger Sohn, Frankfurt, Germany 219-732
2. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13 (1965) 516-530
3. Joffe H.V., and Goldhaber S.Z. Hypercoagulable states and other risk factors for venous thromboembolism. In: Dalen J.E. (Ed). Venous Thromboembolism (2003), Marcel Dekker, New York 11-39
4. Griffin J.H., Evatt B., Zimmerman T.S., et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68 (1981) 1370-1373
5. Comp P.C., Nixon R.R., Cooper M.R., et al. Familial protein S deficiency in association with recurrent thrombosis. J Clin Invest 74 (1984) 2082-2088
6. Hron G., Kollars M., Binder B.R., et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296 (2006) 397-402
7. Christiansen S.C., Cannegieter S.C., Koster T., et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 (2005) 2352-2361
8. Brouwer J.L., Veeger N.J., Kluin-Nelemans H.C., and van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 145 (2006) 807-815
9. van Vlijmen E.F., Brouwer J.L., Veeger N.J., and van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. Arch Intern Med 167 (2007) 282-289
10. Koster T., Rosendaal F.R., Briet E., et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 10 (1995) 2756-2761
11. Crowther M.A., and Kelton J.G. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138 (2003) 128-134
12. Deitcher S.R., and Gomes M.C.P. Hypercoagulable States. Disease Management Project (2003), The Cleveland Clinic Foundation, Cleveland
13. Graf L.L., Welsh C.H., Qamar Z., et al. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 119 (2003) 52-60
14. Dahlback B., and Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant factor activity found to be a property of factor V. Proc Natl Acad Sci U S A 91 (1994) 1396-1400
15. Ho W.K., Hankey G.J., Quinlan D.J., et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia. Arch Intern Med 166 (2006) 729-736
16. Straczek C., Oger E., Jonage-Canonico M.B., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 112 (2005) 3495-3500
17. Auerbach A.D., Sanders G.D., and Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 116 (2004) 816-828
18. Cosmi B., Legnani C., Bernardi F., et al. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 163 (2003) 1105-1109
19. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
20. Legnani C., Palareti G., Guazzaloca G., et al. Venous thromboembolism in young women. Eur Heart J 23 (2002) 984-990
21. Ray J.G. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 158 (1998) 2101-2106
22. Ray J.G., Kearon C., Yi Q., Sheridan P., et al. Homocysteine-lowering therapy and risk for venous thromboembolism. Ann Intern Med 146 (2007) 761-767
23. den Heijer M., Willems H.P., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled double-blind trial. Blood 109 (2007) 139-144
24. Gezer S. Antiphospholipid syndrome. Dis Mon 49 (2003) 696-741
25. Schulman S., Svenungsson E., Granqvist S., and Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104 (1998) 332-338
26. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401S-428S
27. Kyrle P.A., Minar E., Hirschl M., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
28. Vandenbroucke J.P., van der Meer F.J., Helmerhorst F.M., and Rosendaal F.R. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. BMJ 313 (1996) 1127-1130
29. Santamaria A., Mateo J., Oliver A., et al. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 86 (2001) 965-971
30. Hansson P.O., Sorbo J., and Eriksson H. Recurrent venous thromboembolism after deep venous thrombosis: incidence and risk factors. Arch Intern Med 160 (2000) 769-774
31. Prandoni P., Lensing A.W.A., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
32. Baglin T., Luddington R., Brown K., et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003) 523-526
33. de Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341 (1999) 801-806
34. Palareti G., Cosmi B., Legnani C., et al. d-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355 (2006) 1780-1789